Coherus Oncology, Inc. — Earnings Quality Grade F
CHRS · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 154 days, change -1386 days YoY
AR growth -84.0% vs revenue growth 59.8%
Revenue grew 59.8% but CFFO declined -577.7%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
Inventory -24.6% vs COGS 58.3%. Normal
Insufficient data
SG&A/Gross Profit = 354.8%, exceeds 70%
Gross margin 67.2%, change +0.3pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF < 50% of Net Income for 2 years
Accruals ratio = 118.7%. Exceeds 10%
Cash $0.2B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 76% of equity. Over 50%
Interest coverage = -20.1x (<2x). Financial stress
Other assets -92.0% vs revenue 59.8%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -14% YoY. Normal
Manipulation Score
M-Score = 2.93 (> -1.78). LIKELY MANIPULATOR
Small-cap context: Beneish M-Score was calibrated on large-caps; small-cap DSO/inventory volatility mechanically inflates it.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25